Group 1: Market Competition and Strategy - The oral industry is experiencing intensified competition, particularly in the private market, following a brief surge in demand for dental implants, which is now slowing down [4] - The company aims to maintain its competitive edge in the dental sector by implementing precise marketing strategies and enhancing collaboration with leading end-users [4] - The company is actively pursuing product upgrades to adapt to market changes [4] Group 2: Product Development and Sales - The second oral repair membrane will focus on applications for superficial soft tissue defects and gingival mucosa repair [4] - The market demand for the company's meninges products remains stable, with 24 provinces participating in bulk procurement, leading to a decrease in prices but an increase in sales volume [5] - The company plans to continue tracking the progress of bulk procurement projects and respond proactively [5] Group 3: Growth Drivers and Financial Outlook - The company will implement a "precision marketing" strategy to strengthen existing channels and core brands, aiming for revenue growth from existing products [6] - New product approvals, including the second-generation oral repair membrane and calcium silicate bio-ceramic bone repair materials, are expected to enhance the product matrix in the oral field [6] - Sales expense ratio is projected to increase in the second half of 2024 due to intensified marketing efforts, but is expected to return to a reasonable level in 2025 as sales revenue grows [6]

证券代码：300653 证券简称：正海生物 公告编号：2025-022 参加 2025 年山东辖区上市公司投资者网上集体接待日活动的公告 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公 司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 烟台正海生物科技股份有限公司 董 事 会 烟台正海生物科技股份有限公司 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，烟台正海生物科技股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现 ...

Group 1: Market Competition Landscape - The main companies in China's oral medical consumables market include Times Angel, AoJing Medical, and Modern Dental, while the medical devices sector is led by Meiya Optoelectronics, Xianlin 3D, and Xinhua Medical [1] - In the pharmaceutical segment, key players are Shenghua Pharmaceutical, Nanyue Pharmaceutical, and Hengsheng Pharmaceutical, and in the medical services sector, Tongce Medical, Koen Dental, and Lantian Dental are prominent [1] Group 2: Regional Distribution - The oral medical industry in China is concentrated in regions such as Guangdong, Shandong, and Jiangsu, with Guangdong being the most concentrated area [3] Group 3: Dental Implant Market - The high-end dental implant market is primarily dominated by foreign companies such as Straumann, Dentsply, and Nobel, while the mid-to-low-end market is led by domestic brands like Aochitai and Dentium, which face challenges in clinical application and brand establishment compared to imported products [6] Group 4: Orthodontics Market - The orthodontic treatment market includes traditional braces and clear aligners, with Times Angel and Invisalign together holding over 70% of the clear aligner market in China as of 2023 [7] Group 5: Overall Industry Competition Status - There is a notable quality and effectiveness disparity between imported and domestic oral medical consumables and devices, leading to stronger bargaining power for imported suppliers, while domestic suppliers have weaker bargaining power [8] - Large chain dental hospitals have superior equipment and personnel, resulting in lower bargaining power for consumers [8] - The oral medical industry has significant technical barriers and high entry thresholds, making it difficult for new entrants, thus posing a low threat from new competitors [8] - The overall competition level among existing companies in the Chinese oral medical market is moderate, based on factors such as the number of competitors, market concentration, and entry barriers [8]

Core Viewpoint - Zhenghai Biological's stock closed at 20.14 yuan, with a PE ratio of 29.99, marking a 15-day low, and a total market capitalization of 3.625 billion yuan [1] Company Summary - Zhenghai Biological focuses on the research, production, and sales of biological regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, skin repair membranes, surgical packing sponges, self-etching adhesives, active biological bone, dura mater patches, phosphoric acid etchants, and dental sealants [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023 [1] Financial Performance - For Q1 2025, the company reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, while net profit was 26.63 million yuan, reflecting a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1] Industry Summary - The average PE ratio for the medical device industry is 49.20, with a median of 36.56, placing Zhenghai Biological at the 67th position in the industry ranking [2]

股东大会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2025-021 烟台正海生物科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 1 股东大会决议公告 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）2024 年年度股东大会 于 2025 年 5 月 6 日下午 14:30 在烟台经济技术开发区南京大街 7 号烟台正海生 物科技股份有限公司会议室召开，本次会议采取现场投票与网络投票结合的表决 方式。其中： （1）现场会议召开时间：2025 年 5 月 6 日（星期二）下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 6 日的交易时间，即 9:15—9:25，9:30—11:30 和 13:00—15:00；通过 深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 6 日 9:15—15:00。 本次 ...

山东川奇律师事务所 关于烟台正海生物科技股份有限公司 2024 年年度股东大会的 法律意见书 致：烟台正海生物科技股份有限公司 山东川奇律师事务所（以下简称"本所"）接受烟台正海生物科 技股份有限公司（以下简称"公司"）的委托，指派王建洲律师、徐 学广律师（以下合称"本所律师"）列席并见证公司 2024 年度股东 大会（下称"本次股东大会"）。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东大会规则》（以下简称"《股东大 会规则》"）等法律、行政法规及公司《章程》的有关规定，本所律师 按照中国律师行业公认的业务标准、道德规范和勤勉尽责精神，对本 次股东大会的有关事项进行了核查和验证，出具法律意见书。 在本法律意见书中，本所律师根据《股东大会规则》的要求，就 本次股东大会的召集人资格、召集、召开程序是否合法及是否符合公 司《章程》、出席会议人员资格的合法有效性、会议表决程序、表决 方式的合法有效性发表意见。 本所在此同意贵公司将本法律意见书作为本次股东大会的必备 文件予以公告，并依法对本所出具的法律意见书承担责任。 一、本次股东大会的召集人资格及召集、召开程序 ...

股东大会提示性公告 证券代码：300653 证券简称：正海生物 公告编号：2025-020 烟台正海生物科技股份有限公司 关于召开 2024 年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经烟台正海生物科技股份有限公司（以下简称"公司"）第四届董事会第六 次会议审议通过，决定于 2025 年 5 月 6 日（星期二）召开 2024 年年度股东大会。 公司已于 2025 年 4 月 15 日在巨潮资讯网（www.cninfo.com.cn）上披露了《关于 召开 2024 年年度股东大会的通知》（公告编号 2025-013），本次股东大会采用现 场投票和网络投票相结合的方式召开，现将本次股东大会的有关事宜再次提示如 下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 1 股东大会提示性公告 6、会议的股权登记日：2025 年 4 月 25 日（星期五） 2、召集人：公司董事会 3、会议召开的合法、合规性：公司第四届董事会第六次会议审议通过，决 定召开 2024 年年度股东大会，召集程序符合有关法律、行政法规、部门 ...

Financial Performance - In Q1 2025, the company achieved total revenue of 97.42 million yuan, an increase of 8.68% compared to the same period last year [1] - The net profit attributable to shareholders was 26.63 million yuan, a decrease of 34.06% year-on-year [1] - Earnings per share stood at 0.15 yuan [1] Market Position and Competition - The company’s oral product sales have seen a year-on-year increase in Q1 2025, despite missing previous opportunities in the dental implant market [3] - Competitors in the orthopedic sector are actively developing next-generation products, indicating a need for the company to maintain a sense of urgency in its active bone sales [3][4] - The market for bone repair materials is expected to grow steadily, benefiting from the increasing demand in China [4] Product Development and Strategy - The company plans to promote its active biological bone products in UBE surgical applications, leveraging its unique technology that prevents BMP-2 diffusion in water environments [3][4] - There are ongoing efforts to expand the product line, including potential new product development and market entry strategies [4][5] - The company is considering mergers and acquisitions to enhance its product offerings and market presence [4] Sales and Marketing - The company has an independent sales team focused on promoting active biological bone products, with plans to enhance their professional capabilities [6] - The number of distributors has increased to over 1,410 nationwide as of 2024 [7] - The company is committed to a precision marketing strategy to strengthen its market share and brand recognition [6][8] Future Outlook - The company remains optimistic about the future of regenerative medicine and is expanding its technical platforms to include additive manufacturing and synthetic biology [5] - New products, such as the second-generation oral repair membrane and calcium silicate biological bone materials, are expected to enhance the company’s market position [8] - The company is actively monitoring industry trends and regulatory changes to adapt its strategies accordingly [4][8]

提示性公告 证券代码：300653 证券简称：正海生物 公告编号：2025-016 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2025 年 4 月 21 日，烟台正海生物科技股份有限公司（以下简称"公司"） 第四届董事会第七次会议审议通过了《关于公司 2025 年第一季度报告的议案》。 为使投资者全面了解报告期内公司的经营情况和财务状况，公司 2025 年第一季 度报告于 2025 年 4 月 22 日在中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露。 敬请投资者注意查阅。 特此公告。 烟台正海生物科技股份有限公司 董 事 会 2025 年 4 月 22 日 烟台正海生物科技股份有限公司 2025 年第一季度报告披露提示性公告 ...

监事会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2025-019 烟台正海生物科技股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）第四届监事会第六次 会议于 2025 年 4 月 21 日以通讯方式召开，会议通知已于 2025 年 4 月 18 日以电 子邮件形式向全体监事发出。本次会议应到监事 3 人，实到 3 人，其中许月莉、 潘励山、宋广平以通讯方式出席会议，会议由许月莉女士主持。会议的出席人数、 召开和表决方式符合《中华人民共和国公司法》等法律法规及《烟台正海生物科 技股份有限公司章程》的相关规定，合法有效。 二、监事会会议审议情况 经与会监事认真审议，通过如下决议： 1、关于公司 2025 年第一季度报告的议案 经审核，监事会认为董事会编制和审核公司《2025 年第一季度报告》的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏 ...